Bevacizumab and weekly dose-dense paclitaxel and carboplatin in recurrent epithelial ovarian carcinoma: A phase II trial

ADVANCED EPITHELIAL OVARIAN CANCER: THE PROGNOSTIC SIGNIFICANCE OF RESIDUAL DISEASE AFTER CYTOREDUCTIVE SURGERY

Phase II Randomized Trial of Biweekly Bevacizumab, Capecitabine, Oxaliplatin and Irinotecan (BEV- CAPEOXIRI) Versus Triweekly Bevacizumab, Capecitabine and Oxaliplatin (BEV- CAPEO

PRE-OPERATIVE HISTOLOGICAL PARAMETERS AS A PREDICTOR OF CHEMOTHERAPY RESPONSE IN ADVANCED OVARIAN CANCER

Role of Pelvic and Para-Aortic Lymphadenectomy in Advanced Ovarian Epithelial Cancer

Role of Neoadjuvant Chemotherapy Followed by Interval Cyto-Reductive Surgery in Reducing Progression and Recurrence of Patients with Advanced Endometrial Cancer

Interval debulking Surgery after Neoadjuvant Chemotherapy for Advanced Ovarian Carcinoma, Impact on Patients’ Survival

NEOADJUVANT CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIATION FOR LOCALLY ADVANCED HEAD AND NECK CANCERS

PLATINUM BASED VERSUS ANTHRACYCLIN BASED NEOADJUVANT CHEMOTHERAPY IN NONMETASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS

Bevacizumab for the Treatment of Macular Edema